Total Payments
$708.65
2024 Payments
$165.96
Companies
13
Transactions
33
Medicare Patients
18,152
Medicare Billing
$949,207
Payment Breakdown by Category
Food & Beverage$708.65 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $708.65 | 33 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $204.61 | 8 | $0 (2020) |
| Novo Nordisk Inc | $99.84 | 5 | $0 (2024) |
| Celgene Corporation | $65.09 | 4 | $0 (2022) |
| ABBVIE INC. | $62.26 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $59.63 | 3 | $0 (2024) |
| SK Life Science, Inc. | $49.97 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $41.47 | 3 | $0 (2021) |
| BIOTRONIK INC. | $34.11 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $19.96 | 1 | $0 (2023) |
| ZS Pharma. Inc. | $19.95 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $165.96 | 7 | SK Life Science, Inc. ($49.97) |
| 2023 | $160.52 | 8 | Novo Nordisk Inc ($78.77) |
| 2022 | $20.71 | 1 | Celgene Corporation ($20.71) |
| 2021 | $75.56 | 5 | Celgene Corporation ($44.38) |
| 2020 | $30.08 | 2 | EMD Serono, Inc. ($15.06) |
| 2019 | $195.53 | 6 | EMD Serono, Inc. ($161.42) |
| 2018 | $40.34 | 3 | EMD Serono, Inc. ($28.13) |
| 2017 | $19.95 | 1 | ZS Pharma. Inc. ($19.95) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/14/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $21.23 | General |
| 06/12/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $28.74 | General |
| 03/20/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: Diabetes | ||||||
| 03/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Diabetes | ||||||
| 02/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $31.67 | General |
| Category: NEUROSCIENCE | ||||||
| 01/23/2024 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Hepatitis B Vaccine | ||||||
| 01/11/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: RESPIRATORY | ||||||
| 11/22/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Obesity | ||||||
| 09/25/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Obesity | ||||||
| 08/30/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/17/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Diabetes | ||||||
| 08/10/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Diabetes | ||||||
| 08/01/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: RESPIRATORY | ||||||
| 07/26/2023 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.71 | General |
| Category: Neuroscience | ||||||
| 08/26/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.28 | General |
| Category: Neuroscience | ||||||
| 07/22/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.44 | General |
| Category: Neuroscience | ||||||
| 05/13/2021 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: Neuroscience | ||||||
| 03/10/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.24 | General |
| Category: Neuroscience | ||||||
| 02/13/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: HYPERHYDROSIS | ||||||
| 08/14/2020 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.02 | General |
| Category: Neuroscience | ||||||
| 03/04/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: Neurology | ||||||
| 10/01/2019 | EMD Serono, Inc. | Mavenclad (Biological) | Food and Beverage | In-kind items and services | $8.39 | General |
| Category: Neurology | ||||||
| 09/09/2019 | EMD Serono, Inc. | Mavenclad (Biological) | Food and Beverage | In-kind items and services | $23.75 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 3,007 | 4,182 | $696,638 | $182,418 |
| 2022 | 45 | 5,129 | 9,567 | $1.1M | $324,119 |
| 2021 | 52 | 5,298 | 8,391 | $796,871 | $252,495 |
| 2020 | 46 | 4,718 | 7,286 | $666,797 | $190,174 |
Total Patients
18,152
Total Services
29,426
Medicare Billing
$949,207
Procedure Codes
177
All Medicare Procedures & Services
177 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 440 | 860 | $304,628 | $74,313 | 24.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 254 | 254 | $94,008 | $33,358 | 35.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 196 | 463 | $81,025 | $19,863 | 24.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 168 | 459 | $61,965 | $15,575 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 130 | $32,846 | $7,196 | 21.9% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 25 | 27 | $13,860 | $4,399 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $13,215 | $3,349 | 25.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 268 | 357 | $7,140 | $2,999 | 42.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 206 | 206 | $13,390 | $2,703 | 20.2% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 16 | 16 | $5,550 | $2,697 | 48.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 219 | 229 | $11,450 | $2,370 | 20.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 227 | 250 | $8,750 | $1,895 | 21.7% |
| 82306 | Vitamin d-3 level | Office | 2023 | 63 | 65 | $7,800 | $1,857 | 23.8% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 140 | 143 | $5,698 | $1,361 | 23.9% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 55 | 55 | $3,133 | $1,029 | 32.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 52 | 58 | $3,770 | $954.68 | 25.3% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 47 | 47 | $2,491 | $889.24 | 35.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 94 | 95 | $6,301 | $814.26 | 12.9% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 54 | 56 | $2,800 | $748.16 | 26.7% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 13 | 13 | $1,820 | $555.75 | 30.5% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 34 | 35 | $2,100 | $517.30 | 24.6% |
| 83550 | Iron binding capacity | Office | 2023 | 54 | 56 | $1,960 | $479.92 | 24.5% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 11 | 11 | $1,925 | $444.95 | 23.1% |
| 83540 | Iron level | Office | 2023 | 54 | 56 | $1,400 | $355.04 | 25.4% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 22 | 22 | $910.00 | $315.63 | 34.7% |
About Dr. Baljinder Singh, MD
Dr. Baljinder Singh, MD is a Internal Medicine healthcare provider based in Raynham, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1760660492.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Baljinder Singh, MD has received a total of $708.65 in payments from pharmaceutical and medical device companies, with $165.96 received in 2024. These payments were reported across 33 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($708.65).
As a Medicare-enrolled provider, Singh has provided services to 18,152 Medicare beneficiaries, totaling 29,426 services with total Medicare billing of $949,207. Data is available for 4 years (2020–2023), covering 177 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Raynham, MA
- Active Since 02/05/2008
- Last Updated 04/01/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1760660492
Products in Payments
- Mavenclad (Biological) $146.92
- ZEPOSIA (Drug) $94.35
- Rebif (Biological) $42.63
- Ozempic (Drug) $42.27
- Wegovy (Drug) $36.50
- QULIPTA (Drug) $31.67
- TRELEGY ELLIPTA (Drug) $31.20
- VRAYLAR (Drug) $30.59
- AREXVY (Drug) $28.43
- Rybelsus (Drug) $21.07
- FARXIGA (Drug) $19.96
- BRILINTA (Drug) $19.95
- Heplisav-B (Drug) $19.55
- BOTOX (Biological) $16.94
- JARDIANCE (Drug) $15.27
- Mavenclad (Drug) $15.06
- OPDIVO (Biological) $12.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.